Bicara Therapeutics Inc.

Bicara Therapeutics Inc. (BCAX) priced its initial public offering on Sep 13, 2024 at $18.00 per share, within its $16.00–$18.00 range, raising $315M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $931.7M. Morgan Stanley was lead-left underwriter, joined by TD Cowen, Cantor and Stifel. Goodwin Procter advised the company and Ropes & Gray advised the underwriters.

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. Its lead program, ficerafusp alfa, combines an EGFR-directed antibody with a domain binding TGF-beta.

Status

IPO

Ticker

BCAX

Exchange

Nasdaq Global Market

Priced

Sep 13, 2024

IPO price

$18.00

Price range

$16.00–$18.00

Raised

$315M

Market cap at IPO price

$931.7M

First filed

Aug 22, 2024

Underwriters

Morgan Stanley, TD Cowen, Cantor and Stifel

Company counsel

Goodwin Procter

Underwriters' counsel

Ropes & Gray

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.